Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00879658
Recruitment Status : Completed
First Posted : April 10, 2009
Last Update Posted : March 2, 2018
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )